Latest & greatest articles for dementia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dementia

961. Strategies for managing behavioural symptomatology associated with dementia of the Alzheimer type: a systematic overview

Strategies for managing behavioural symptomatology associated with dementia of the Alzheimer type: a systematic overview Strategies for managing behavioural symptomatology associated with dementia of the Alzheimer type: a systematic overview Strategies for managing behavioural symptomatology associated with dementia of the Alzheimer type: a systematic overview Forbes D A Authors' objectives To assess and summarise research evidence on the effectiveness of strategies within the scope of nursing (...) in managing the behavioural symptomatology associated with dementia of the Alzheimer type in elderly individuals. Searching MEDLINE, CINAHL, PsycINFO, Sociofile, Ageline, HealthSTAR, Dissertation Abstracts, Government Documents (First Search), and CAN Research Index were searched from January 1985 to April 1997. The search terms were provided. Key journals such as The Gerontologist and the Journal of the American Geriatrics Society were manually searched and several key informants were contacted

1998 DARE.

962. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia

Efficacy and safety of neuroleptics in behavioral disorders associated with dementia Efficacy and safety of neuroleptics in behavioral disorders associated with dementia Efficacy and safety of neuroleptics in behavioral disorders associated with dementia Lanctot K L, Best T S, Mittmann N, Liu B A, Oh P I, Einarson T R, Naranjo C A Authors' objectives To compare the efficacy and safety of neuroleptics versus placebo in the treatment of behavioural disorders in patients with dementia. Searching (...) MEDLINE was searched from 1966 to 1995 for publications in the English language. The keywords were 'antipsychotic agents', 'phenothiazines', or 'butyrophenones'; and 'dementia'; and 'behavior therapy' or 'behavior'. Additional material was identified by the manual cross-referencing of recent reviews and the retrieved papers, and by consulting experts. Study selection Study designs of evaluations included in the review The included studies were randomised controlled trials (RCTs) of at least one

1998 DARE.

963. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. (PubMed)

A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. EGb 761 is a particular extract of Ginkgo biloba used in Europe to alleviate symptoms associated with numerous cognitive disorders. Its use in dementias is based on positive results from only a few controlled clinical trials, most of which did not include standard assessments of cognition and behavior.To assess the efficacy and safety of EGb in Alzheimer disease (...) and multi-infarct dementia.A 52-week, randomized double-blind, placebo-controlled, parallel-group, multicenter study.Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia, without other significant medical conditions.Patients assigned randomly to treatment with EGb (120 mg/d) or placebo. Safety, compliance, and drug dispensation were monitored every 3 months with complete outcome evaluation at 12, 26, and 52 weeks.Alzheimer's Disease Assessment Scale-Cognitive subscale

1997 JAMA

964. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT)

Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stein K (...) . Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT) Southampton: Wessex Institute for Health Research and Development (WIHRD) 1997 Authors' objectives Donepezil is a new drug treatment, recently licensed in the UK, for use in mild to moderate dementia due to senile dementia of the Alzheimer type (SDAT). The author assesses whether it should be made available to all patients with mild to moderate SDAT. Authors' conclusions The effectiveness of donepezil in routine

1997 Health Technology Assessment (HTA) Database.

965. Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients

Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients Mintzer J E, Colenda C, Waid L R, Lewis L, Meeks A, Stuckey M, Bachman D L, Saladin M, Sampson R R Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A continuum of care using brief and partial hospitalizationfor agitated dementia patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with different ethnic backgrounds diagnosed with both

1997 NHS Economic Evaluation Database.

966. Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test

Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test Methods of screening for dementia: a meta-analysis of studies comparing an informant questionnaire with a brief cognitive test Jorm A F Authors' objectives To clarify the relative performance of an informant questionnaire with a brief cognitive (...) test in screening for dementia, or dementia plus delirium. Searching MEDLINE and PsycLIT were searched using the keywords 'dementia' or 'cognitive' and 'informant' or 'proxy'. The review by Jorm 1996 (see Other Publications of Related Interest) was searched for citations, as were the reference lists of all located studies, and researchers in the area (including the authors of all known informant questionnaires) were contacted. Study selection Study designs of evaluations included in the review

1997 DARE.

967. Is senile dementia "age-related" or "ageing-related"?--evidence from meta-analysis of dementia prevalence in the oldest old. (PubMed)

Is senile dementia "age-related" or "ageing-related"?--evidence from meta-analysis of dementia prevalence in the oldest old. The observation of an exponential increase in senile dementia prevalence with age has led to the conclusion that this disease may be inevitable in those who live long enough. The alternative view is that at very high ages the prevalence rate levels off. Studies conducted to date have not included sufficient numbers of very old people to resolve this difference of opinion (...) . The question is important both to our understanding of the biological mechanisms involved and for public health planning. We have carried out a meta-analysis of nine epidemiological studies of senile dementia that used DSM III diagnostic criteria and that included samples of elderly people over age 80. The resulting curve was best described as a flattened S curve that fitted a modified logistic function rather than an exponential pattern. The rate of increase in senile dementia prevalence was found to fall

1995 Lancet

968. Cost-utility analysis of group living in dementia care

Cost-utility analysis of group living in dementia care Cost-utility analysis of group living in dementia care Cost-utility analysis of group living in dementia care Wimo A, Mattson B, Krakau I, Eriksson T, Nelvig A, Karlsson G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Care settings for dementia patients. Type of intervention Secondary prevention Economic study type Cost-utility analysis Study population Elderly people with dementia. The mean age of patients was 79 with a ratio of approximately 2 Setting The three different residence regimes of group living, home living and institutional living were compared in Sundsvall, an industrial city in central Sweden. Dates to which data relate Patients were admitted

1995 NHS Economic Evaluation Database.

969. Effects of respite care on patients with dementia and their caregivers

Effects of respite care on patients with dementia and their caregivers Effects of respite care on patients with dementia and their caregivers Effects of respite care on patients with dementia and their caregivers Flint A J Authors' objectives To determine the effect of formal respite care on patients with dementia and their caregivers. Searching Searches were made of MEDLINE, PsycINFO and Cinahl databases from 1975 to 1994 for English language articles using the words 'respite care' with each (...) of the following: 'dementia', 'Alzheimer's diseas'e and' multi-infarct dementia'. Bibliographies of retrieved articles were searched for additional references. Study selection Study designs of evaluations included in the review Controlled trials of a defined respite intervention in a sample of patients which included a dementia population were included. Selected studies had to be original research in which treatment and control groups were randomised or had baseline comparability. Study durations ranged from 2

1995 DARE.

970. The costs and benefits of a screening program to detect dementia in older drivers

The costs and benefits of a screening program to detect dementia in older drivers The costs and benefits of a screening program to detect dementia in older drivers The costs and benefits of a screening program to detect dementia in older drivers Retchin S M, Hillner B E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Using the Mini-Mental State Examination (MMSE) to screen for dementia in older car drivers. Type of intervention Screening Economic study type cost-effectiveness analysis. Study population A hypothetical cohort of drivers aged 65 and above. Setting A hypothetical non-clinic setting (also relevant to primary care). The economic study was carried out in Virginia, USA. Dates to which data relate

1994 NHS Economic Evaluation Database.

971. Special care units for people with Alzheimer's and other dementias: consumer education, research, regulatory and reimbursement issues

Special care units for people with Alzheimer's and other dementias: consumer education, research, regulatory and reimbursement issues Special care units for people with Alzheimer's and other dementias: consumer education, research, regulatory and reimbursement issues Special care units for people with Alzheimer's and other dementias: consumer education, research, regulatory and reimbursement issues Office of Technology Assessment Record Status This is a bibliographic record of a published (...) health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. Special care units for people with Alzheimer's and other dementias: consumer education, research, regulatory and reimbursement issues. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1992: 204 Authors' objectives

1992 Health Technology Assessment (HTA) Database.

972. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. (PubMed)

Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine. To see whether combined treatment with oral tacrine (tetrahydroaminoacridine; THA) and lecithin improves the symptoms of patients with Alzheimer's disease.Multicentre double blind, placebo controlled, random order crossover trial with individual determination of maximum tolerated dosage and four month follow up.Outpatient

Full Text available with Trip Pro

1990 BMJ

973. Confused minds, burdened families: finding help for people with Alzheimer's and other dementias

Confused minds, burdened families: finding help for people with Alzheimer's and other dementias Confused minds, burdened families: finding help for people with Alzheimer's and other dementias Confused minds, burdened families: finding help for people with Alzheimer's and other dementias Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently (...) been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. Confused minds, burdened families: finding help for people with Alzheimer's and other dementias. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1990: 424 Authors' objectives To develop and analyze Federal policy options for a system to help locate and arrange appropriate services for people with dementia. Authors' conclusions

1990 Health Technology Assessment (HTA) Database.

974. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. (PubMed)

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. We treated 17 patients who had moderate to severe Alzheimer's disease with oral tetrahydroaminoacridine (THA), a centrally active anticholinesterase, in a three-phase study. In the nonblinded first phase of the study, significant improvement occurred in subjects who received the drug, as compared with their pretreatment status, on the global assessment (P = 0.001), the Orientation Test (P = 0.001

1986 NEJM